Immortalization_NN
of_IN
CD4_NN
-LRB-_-LRB-
+_NN
-RRB-_-RRB-
and_CC
CD8_NN
-LRB-_-LRB-
+_NN
-RRB-_-RRB-
T_NN
lymphocytes_NNS
by_IN
human_JJ
T-cell_NN
leukemia_NN
virus_NN
type_NN
1_CD
Tax_NN
mutants_NNS
expressed_VBD
in_IN
a_DT
functional_JJ
molecular_JJ
clone_NN
._.

The_DT
human_JJ
T-cell_NN
leukemia_NN
virus_NN
type_NN
1_CD
-LRB-_-LRB-
HTLV-1_NN
-RRB-_-RRB-
transcriptional_JJ
trans-activator_NN
Tax_NN
has_VBZ
been_VBN
demonstrated_VBN
to_TO
have_VB
transforming_VBG
activity_NN
in_IN
multiple_JJ
cell_NN
culture_NN
and_CC
transgenic-mouse_JJ
models_NNS
._.

In_IN
addition_NN
to_TO
activating_VBG
transcription_NN
from_IN
the_DT
viral_JJ
long_JJ
terminal_JJ
repeat_NN
-LRB-_-LRB-
LTR_NN
-RRB-_-RRB-
through_IN
the_DT
cyclic_JJ
AMP_NN
response_NN
element_NN
binding_NN
protein\/activating_VBG
transcription_NN
factor_NN
-LRB-_-LRB-
CREB\/ATF_NN
-RRB-_-RRB-
family_NN
of_IN
transcription_NN
factors_NNS
,_,
Tax_NN
activates_VBZ
the_DT
expression_NN
of_IN
multiple_JJ
cellular_JJ
promoters_NNS
through_IN
the_DT
NF-kappaB_NN
pathway_NN
of_IN
transcriptional_JJ
activation_NN
._.

The_DT
Tax_NN
mutants_NNS
M22_NN
and_CC
M47_NN
have_VBP
previously_RB
been_VBN
demonstrated_VBN
to_TO
selectively_RB
abrogate_VB
the_DT
ability_NN
of_IN
Tax_NN
to_TO
activate_VB
transcription_NN
through_IN
the_DT
NF-kappaB_NN
or_CC
CREB\/ATF_NN
pathway_NN
,_,
respectively_RB
._.

These_DT
mutations_NNS
were_VBD
introduced_VBN
in_IN
the_DT
tax_NN
gene_NN
of_IN
the_DT
ACH_NN
functional_JJ
molecular_JJ
clone_NN
of_IN
HTLV-1_NN
,_,
and_CC
virus_NN
produced_VBN
from_IN
the_DT
mutant_JJ
ACH_NN
clones_NNS
was_VBD
examined_VBN
for_IN
the_DT
ability_NN
to_TO
replicate_VB
and_CC
immortalize_VB
primary_JJ
human_JJ
lymphocytes_NNS
._.

While_IN
virus_NN
derived_VBN
from_IN
the_DT
clone_NN
containing_VBG
the_DT
M47_NN
mutation_NN
retained_VBD
the_DT
ability_NN
to_TO
immortalize_VB
T_NN
lymphocytes_NNS
,_,
the_DT
M22_NN
mutant_NN
lost_VBD
the_DT
ability_NN
to_TO
immortalize_VB
infected_JJ
cells_NNS
._.

These_DT
results_NNS
indicate_VBP
that_IN
activation_NN
of_IN
the_DT
CREB\/ATF_NN
pathway_NN
by_IN
Tax_NN
is_VBZ
dispensable_JJ
for_IN
the_DT
immortalization_NN
of_IN
T_NN
cells_NNS
by_IN
HTLV-1_NN
,_,
whereas_IN
activation_NN
of_IN
the_DT
NF-kappaB_NN
pathway_NN
may_MD
be_VB
critical_JJ
._.

